Contents

Editorial commentary
1299 Optinurin inclusions in proximal hereditary motor and sensory neuropathy (HMSN-P): familial amyotrophic lateral sclerosis with sensory neuropathy?
M Nakagawa

Neuropsychiatry
1300 Diagnosis and treatment of psychogenic parkinsonism
J Jankovic

1304 Grey matter abnormality in autism spectrum disorder: an activation likelihood estimation meta-analysis study
F Cauda, E Geda, K Sacco, F D’Agata, S Duca, G Geminiani, R Keller

1314 Xenomelia: a new right parietal lobe syndrome
P D McGech, D Beang, T Song, R R Lee, M Huang, V S Ramachandran

1320 Dissecting the Gilles de la Tourette spectrum: a factor analytic study on 639 patients
A E Cavanna, H D Critchley, M Orth, J S Stern, M-B Young, M M Robertson

1324 Delayed experience of volition in Gilles de la Tourette syndrome
G Moreto, P Schwingenschniz, P Katschnig, K P Bhatia, P Haggard

Epilepsy
1328 Seizure recurrence after antiepileptic drug withdrawal and the implications for driving: further results from the MRC Antiepileptic Drug Withdrawal Study and a systematic review
L J Bonnett, A Shukralla, C Tudur-Smith, P R Williamson, A G Marson

1334 Detecting deficits of sustained visual attention in delirium

1341 Structural neuroanatomy of face processing in frontotemporal lobar degeneration
R Omars, J D Rohrer, J C Hallstone, J D Warrren

Multiple sclerosis
1344 Mitoxantrone prior to interferon-beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial
G Edan, G Comi, E Le Page, E Leray, M A Rocca, M Filipi, for The French–Italian Mitoxantrone Interferon-beta-1b Trial Group

1351 Familial recurrence risks for multiple sclerosis in Australia
C O’Gorman, S Freeman, B V Taylor, H Buzzkueen, Australian and New Zealand MS Genetics Consortium (ANZgene), S A Broadway

1355 Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica

1360 Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes
A Nagashiki, M Takaqi, A Uemura, M Tanaka, Y Kitagawa, M Matsui, M Nishizawa, K Sakimura, K Tanaka

Cerebrovascular disease
1365 Factors associated with quality of life in 7-year survivors of stroke
M J Leach, S L Gall, H M Dewey, R A L Macdonnell, A G Thrift

1372 Mutations in TGFB2 gene cause spontaneous cerebral artery dissection
A Pezzi, B Dera, E Del Zotto, M Rietti, M Carletii, G Tonelleri, P Bovi, A Gissi, I Velonghi, P Costa, M Magoni, A Padovan, S Barlati, M Colombi

Vol. 82 | Issue 12 | JNNP December 2011
**Neurosurgery**

1375 Hippocampal resection length and memory outcome in selective epilepsy surgery
C Helmstaedter, S Roeske, S Kaaden, C E Elger, J Schramm

1390 Once-weekly risedronate for prevention of hip fracture in women with Parkinson’s disease: a randomised controlled trial
Y Sato, J Iwamoto, Y Honda

**Movement disorders**

1382 Urinary dysfunction in early and untreated Parkinson’s disease
T Uchiyama, R Sakakibara, T Yamamoto, T Ito, C Yamaguchi, Y Awa, M Yanagisawa, Y Higuchi, Y Sato, T Ichikawa, T Yamanishi, T Hattori, S Kuwabara

1387 Maximal subthalamic beta hypersynchrony of the local field potential in Parkinson’s disease is located in the central region of the nucleus
C de Solages, B C Hill, H Yu, J M Henderson, H Bronte-Stewart

1394 Muscle ischaemia in patients with orthostatic hypotension assessed by velocity recovery cycles
A M Humm, H Bostock, R Troller, W J Z’Graggen

**Neuromuscular disease**

1399 Antiglycine-receptor encephalomyelitis with rigidity
N Mas, A Saiz, M I Leite, P Waters, M Baron, D Castaño, L Sabater, A Vincent, F Graus

**Neuro-inflammatory disease**

1399 Antiglycine-receptor encephalomyelitis with rigidity
N Mas, A Saiz, M I Leite, P Waters, M Baron, D Castaño, L Sabater, A Vincent, F Graus

**PostScript**

1402 Letters